Do SARMs Really Build Muscle? What the Evidence Actually Shows

What SARMs Are and How They Differ From Steroids

SARMs are synthetic small molecules designed to bind selectively to the androgen receptor. The goal behind their development was straightforward: produce the anabolic effects of testosterone on muscle and bone while avoiding androgenic side effects in tissues like the prostate, skin, and liver. Traditional anabolic-androgenic steroids (AAS) bind the androgen receptor indiscriminately, which explains their broader side-effect profile.

The selectivity argument is partly real and partly marketing. SARMs do activate androgen receptors in skeletal muscle with reasonable tissue preference, but "selective" does not mean side-effect-free. The receptor is present in the hypothalamus and pituitary, which is exactly why every SARM studied to date suppresses the hypothalamic-pituitary-testicular axis (HPTA) to some degree. Research published in JAMA Internal Medicine found that roughly 44% of 44 commercially available SARM products contained no SARMs at all, about 25% contained unapproved drugs not listed on the label, and only 52% of products contained the compound listed.

The most studied compounds in human trials include:

• LGD-4033 (ligandrol) by Ligand Pharmaceuticals
• MK-2866 (ostarine / enobosarm) by GTx
• RAD-140 (testolone)
• MK-677 (ibutamoren), technically a growth hormone secretagogue, not a true SARM, though it is widely grouped and sold with them

SARMs are not approved for any medical use in the United States. The FDA has issued more than 17 warning letters to SARM manufacturers and distributors since 2017, noting these compounds may cause liver toxicity, heart attack, and stroke.

The Actual Clinical Trial Data on Muscle Gain

SARMs do build muscle. The question is how much, under what conditions, and at what cost.

The most cited human data come from a Phase I dose-escalation trial of LGD-4033 published in the Journals of Gerontology. In that randomized, double-blind, placebo-controlled trial (N=76 healthy men), Basaria et al. found that LGD-4033 increased lean body mass dose-dependently. At 1 mg per day for 21 days, participants gained 1.21 kg of lean mass compared to placebo. Stair-climbing power also improved. Those results sound promising until you read the rest of the paper: total testosterone fell from approximately 600 ng/dL to roughly 200 ng/dL at the 1 mg dose, sex hormone-binding globulin dropped, and free testosterone was suppressed at all doses. HDL cholesterol fell 19% at the highest dose tested.

Ostarine has a larger clinical footprint because GTx pursued it for cancer cachexia and stress urinary incontinence. The ENOBOSARM-1 and ENOBOSARM-2 Phase III trials (combined N=over 600 cancer patients) showed statistically significant improvements in lean body mass at 3 mg per day over 12 weeks, but the trials failed their co-primary endpoints for physical function, and the FDA did not approve the compound. Lean mass gains in the ostarine trials ranged from 1.4 to 3.3 kg depending on dose and population.

RAD-140 and other newer SARMs lack peer-reviewed Phase II or Phase III human data entirely. What circulates online as "RAD-140 results" is overwhelmingly anecdotal or derived from rodent pharmacology studies, where tissue selectivity looks far cleaner than it does in humans.

To put SARM-induced gains in context, consider the comparison point. A landmark NEJM study by Bhasin et al. showed that men given 600 mg testosterone enanthate per week for 10 weeks gained 6.1 kg of lean mass without any exercise, compared to 1.9 kg in placebo-plus-exercise controls. SARMs at typical self-administered doses produce gains meaningfully smaller than supraphysiologic testosterone, though the androgenic side-effect burden is also lower, at least in short-term trials.

Are SARMs Legal to Buy, Own, or Use?

The legal picture has several layers, and the answer depends on whether you are asking about personal possession, competitive sport, or retail sale.

In the United States: SARMs are not scheduled controlled substances under the Controlled Substances Act as of mid-2025, so personal possession is generally not a federal crime. However, selling SARMs as dietary supplements or for human consumption is illegal under the Federal Food, Drug, and Cosmetic Act. The SARMs Control Act, introduced in Congress multiple times since 2018, would classify SARMs as Schedule III controlled substances if passed, but it had not been enacted as of this article's publication date.

In competitive sport: The World Anti-Doping Agency (WADA) has prohibited all SARMs under Section S1 (Anabolic Agents) since 2008. WADA's prohibited list makes no exception for any SARM at any dose. Athletes across Olympic, collegiate (NCAA), and professional leagues face multi-year bans for positive tests.

Quality control reality: Because SARMs exist in a regulatory gray zone, they are often manufactured without pharmaceutical-grade oversight. The JAMA Internal Medicine analysis cited above found dose inaccuracies of up to 3-fold in tested products. That means a label claiming "10 mg ostarine" may contain anywhere from near zero to over 30 mg of active compound, or a completely different drug.

Does Every SARM Cycle Require PCT?

Yes. Post-cycle therapy is almost always warranted after a SARM cycle, and skipping it carries real risk of prolonged hypogonadism.

Every SARM that has been tested in humans produces measurable HPTA suppression. In the LGD-4033 trial, testosterone levels had not fully recovered to baseline at the 5-week post-treatment measurement point for participants in the higher-dose groups. The degree of suppression correlates with dose, cycle length, and whether multiple SARMs are stacked.

A case series published in the Annals of Internal Medicine documented prolonged hypogonadism in a 24-year-old man following a self-administered ostarine cycle. His total testosterone was 61 ng/dL on presentation, and he required clinical management for months before recovering endogenous production.

Standard PCT protocols borrowed from AAS use include:

• Clomiphene citrate (Clomid): typically 25 to 50 mg per day for 4 to 6 weeks, acting as a selective estrogen receptor modulator (SERM) that increases gonadotropin release
• Tamoxifen (Nolvadex): 20 to 40 mg per day for 4 to 6 weeks, same mechanism
• Enclomiphene: the trans-isomer of clomiphene, sometimes preferred for its cleaner receptor pharmacology, though data specific to SARM PCT are sparse

No randomized controlled trial has tested a PCT protocol specifically in the context of SARM suppression. The protocols above are extrapolated from AAS recovery data, which means their dosing and duration for SARM users are not evidence-based in a strict sense. The Endocrine Society's clinical practice guideline on male hypogonadism does not address SARM-induced suppression specifically, though it provides the framework used by clinicians managing these patients.

Any man experiencing symptoms of low testosterone after a SARM cycle (fatigue, reduced libido, mood changes, loss of morning erections) should get a full hormonal panel before starting PCT rather than self-medicating.

Is Anavar Safer Than Other Steroids, and How Does It Compare to SARMs?

Oxandrolone (brand name Anavar) is a 17-alpha-alkylated oral anabolic steroid with a relatively low androgenic-to-anabolic ratio. It was originally developed for muscle wasting in HIV/AIDS and burn injury, and it remains FDA-approved for those indications.

Compared to compounds like trenbolone, nandrolone, or high-dose testosterone, oxandrolone is generally considered milder. The word "safer" needs qualification, though. Oxandrolone is hepatotoxic due to its 17-alpha-alkylation, and a case-control analysis linked oral 17-alpha-alkylated steroids including oxandrolone to elevated liver enzyme levels and, in rare cases, peliosis hepatis. It also suppresses the HPTA, reduces HDL cholesterol, and carries virilization risk in women.

Relative to SARMs on paper, oxandrolone has the advantage of being an FDA-regulated pharmaceutical with known purity when obtained through a pharmacy. Illicitly sourced oxandrolone carries the same contamination risks as any unregulated product. Relative to SARMs, oxandrolone may produce more androgenic side effects in women and similar hepatotoxic risk in both sexes.

The honest comparison: both classes produce real lean-mass gains, both suppress the HPTA, both carry liver risk, and neither should be used for body composition purposes outside of physician supervision. Choosing one over the other for "safety" reasons alone is not a well-supported rationale.

Will SARMs Show Up on a Drug Test?

Yes. Modern anti-doping laboratories can detect most SARMs in urine for weeks after the last dose.

WADA-accredited labs use liquid chromatography tandem mass spectrometry (LC-MS/MS), which can detect LGD-4033, ostarine, RAD-140, and their metabolites at concentrations as low as nanograms per liter. Detection windows vary by compound and dose. A pharmacokinetic study on LGD-4033 found that the parent compound and its major metabolite M1 remained detectable in urine for at least 2 weeks after a single 1 mg dose. Higher doses extend that window proportionally.

Standard workplace urine immunoassay panels (the 5-panel or 10-panel tests common in employment screening) do not test for SARMs. Those panels screen for THC metabolites, cocaine, opioids, amphetamines, and PCP. So a person subject only to routine workplace testing faces no detection risk from SARMs via standard panels.

Athletic drug tests are a different matter entirely. WADA, USADA, NCAA, and most professional sports organizations use LC-MS/MS panels that specifically target SARMs. A single dose of ostarine has produced positive tests in athletes who claimed contaminated supplements, and the Court of Arbitration for Sport has upheld bans in multiple such cases under the strict liability standard.

The contamination problem creates a non-trivial risk even for athletes who believe they are not using SARMs. Because SARM compounds are found in products labeled as protein powders, pre-workouts, and testosterone boosters, inadvertent ingestion is a documented route to positive tests.

The Liver Injury and Cardiovascular Signals Worth Taking Seriously

Regulatory agencies have not elevated SARMs to Schedule III status arbitrarily. The hepatotoxicity signal is real.

The FDA published a safety communication in 2017 describing cases of liver toxicity in people using SARM-containing supplements, including one case of acute liver failure requiring transplantation. A published case series in BMJ Open Sport and Exercise Medicine documented five cases of SARM-associated drug-induced liver injury, with onset between 2 and 12 weeks into use, presenting with jaundice, elevated ALT values above 15 times the upper limit of normal, and in some cases cholestatic patterns requiring corticosteroid treatment.

The cardiovascular picture is less complete but concerning. LGD-4033 reduced HDL cholesterol by 19% at 1 mg per day in a healthy male population. HDL suppression is a recognized cardiovascular risk factor, and the magnitude seen with even low-dose SARMs compares unfavorably to what is seen with physiologic testosterone replacement. Longer exposures at the doses typically self-administered (often 10 to 20 mg per day, not 1 mg) may produce larger lipid shifts, though no long-duration cardiovascular outcomes trial exists.

The absence of long-term safety data cuts both ways. It does not mean SARMs are safe. It means we do not yet know the magnitude of harm from multi-year or high-dose use, and that uncertainty itself is clinically meaningful.

Who Is Actually Prescribing or Recommending SARMs?

No US physician can legally prescribe SARMs for muscle building because no SARM carries FDA approval for that indication. Compounding pharmacies are also prohibited from compounding unapproved SARMs for human use.

Physicians who treat body-composition concerns have other approved tools. Testosterone replacement therapy (TRT) for men with diagnosed hypogonadism (total testosterone below 300 ng/dL per Endocrine Society criteria) produces well-characterized lean-mass gains with a far deeper safety database than any SARM. A meta-analysis of 26 RCTs published in JCEM found that testosterone therapy increased fat-free mass by 1.6 kg on average across diverse populations.

For women seeking body-composition support, low-dose testosterone (transdermal, typically 0.5 to 2 mg per day) and, in some contexts, anabolic agents like oxandrolone carry more regulatory and clinical infrastructure than any SARM currently does.

The practical takeaway for anyone evaluating SARMs for muscle building is this: the gains documented in short trials are real but modest, the suppression of the HPTA is real and requires management, the legal and safety frameworks are thin, and the product quality on the open market is unreliable. Anyone seriously interested in body-composition optimization should discuss TRT candidacy, structured resistance-training programming, and nutrition optimization with a clinician before considering any unapproved compound.